The New England journal of medicine, 2022-02, Vol.386 (6), p.531-543
- Dunkle, Lisa M
- Kotloff, Karen L
- Gay, Cynthia L
- Áñez, Germán
- Adelglass, Jeffrey M
- Barrat Hernández, Alejandro Q
- Harper, Wayne L
- Duncanson, Daniel M
- McArthur, Monica A
- Florescu, Diana F
- McClelland, R. Scott
- Garcia-Fragoso, Veronica
- Riesenberg, Robert A
- Musante, David B
- Fried, David L
- Safirstein, Beth E
- McKenzie, Mark
- Jeanfreau, Robert J
- Kingsley, Jeffrey K
- Henderson, Jeffrey A
- Lane, Dakotah C
- Ruíz-Palacios, Guillermo M
- Corey, Lawrence
- Neuzil, Kathleen M
- Coombs, Robert W
- Greninger, Alex L
- Hutter, Julia
- Ake, Julie A
- Smith, Katherine
- Woo, Wayne
- Cho, Iksung
- Glenn, Gregory M
- Dubovsky, Filip
2022
Details
- Autor(en) / Beteiligte
- Dunkle, Lisa M
- Kotloff, Karen L
- Gay, Cynthia L
- Áñez, Germán
- Adelglass, Jeffrey M
- Barrat Hernández, Alejandro Q
- Harper, Wayne L
- Duncanson, Daniel M
- McArthur, Monica A
- Florescu, Diana F
- McClelland, R. Scott
- Garcia-Fragoso, Veronica
- Riesenberg, Robert A
- Musante, David B
- Fried, David L
- Safirstein, Beth E
- McKenzie, Mark
- Jeanfreau, Robert J
- Kingsley, Jeffrey K
- Henderson, Jeffrey A
- Lane, Dakotah C
- Ruíz-Palacios, Guillermo M
- Corey, Lawrence
- Neuzil, Kathleen M
- Coombs, Robert W
- Greninger, Alex L
- Hutter, Julia
- Ake, Julie A
- Smith, Katherine
- Woo, Wayne
- Cho, Iksung
- Glenn, Gregory M
- Dubovsky, Filip
- Titel
- Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- Ist Teil von
- The New England journal of medicine, 2022-02, Vol.386 (6), p.531-543
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- NVX-CoV2373 is a vaccine containing a full-length stabilized recombinant spike protein trimer that is administered in two doses 3 weeks apart along with a saponin-based adjuvant. In a randomized trial, approximately 20,000 participants received the vaccine and 10,000 a placebo. Vaccine efficacy against infection was 90%, and reactogenicity was similar to that of other Covid-19 vaccines.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2116185Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8693692
- Format
- –
- Schlagworte
- Adolescent, Adult, Age, Aged, Clinical trials, Coronavirus, Coronaviruses, COVID-19, COVID-19 - diagnosis, COVID-19 - epidemiology, COVID-19 - prevention & control, COVID-19 Nucleic Acid Testing, COVID-19 vaccines, COVID-19 Vaccines - adverse effects, Disease prevention, Genomes, Humans, Incidence, Infections, Infectious Disease, Male, Medical laboratories, Mexico, Middle Aged, Nanoparticles, Original, Pandemics, Placebos, Polymerase chain reaction, Population, Proteins, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, Single-Blind Method, Site selection, Spike protein, Statistical analysis, United States, Vaccine Efficacy, Vaccines